Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Epigenetic Regulation01:37

Epigenetic Regulation

3.6K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.6K
Epigenetic Regulation01:46

Epigenetic Regulation

33.3K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

3.1K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.1K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.5K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.5K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS.

Blood neoplasia·2026
Same author

Structure-guided design of 7-azaindole DNMT1 inhibitors active against hypomethylating agent-resistant acute myeloid leukemia.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Reduced Maintenance DNA Methylation Thresholds Enable Sensitive Reporter Assays for UHRF1 and DNMT1 Inhibition.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Cell-free DNA fragmentomes for noninvasive detection of liver cirrhosis and other diseases.

Science translational medicine·2026
Same author

Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial.

Communications medicine·2026
Same author

Importance of De Novo Gene Evolution to Emerging Viral Threats: The ORF10 Strain-Restricted Orphan Gene of SARS-CoV-2 Promotes Pathogenesis.

Molecular biology and evolution·2025

関連する実験動画

Updated: Dec 23, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.8K

エピテリオイド・サルコマのエピジェニック療法

Scott B Rothbart1, Stephen B Baylin2

  • 1Center for Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA.

Cell
|April 18, 2020
PubMed
まとめ

タゼメトスタットは 固体腫瘍に対する エピジェネティック・セラピーです エピテリオイド・サーコマのようなSWI/SNF変異を有するがんの治療に有望な結果を示しています.

科学分野:

  • 腫瘍学
  • エピジェネティクス
  • 分子生物学

背景:

  • タゼメトスタットは,固体腫瘍に対するFDAの承認を受けた新種のエピジェネティック療法です.
  • 特にEZH2を標的としたリシンメチルトランスファーゼ阻害剤として機能する.
  • EZH2は,複合体抑制複合体2 (PRC2) の重要な構成要素であり,転写静止に関与する.

研究 の 目的:

  • タゼメトスタットが先駆的な エピジェネティック・セラピーの 重要性を強調するためです
  • EZH2を標的としたタゼメトスタットの作用メカニズムを解明する.
  • EZH2阻害に敏感な腫瘍タイプ,特にSWI/SNF変異を有する腫瘍を特定する.

主な方法:

  • タゼメトスタットに関する臨床試験データとFDAの承認情報をレビューする.
  • EZH2の生化学分析とPRC2複合体におけるその役割
  • 様々な腫瘍におけるSWI/SNF染色体の複合変異の遺伝子解析

主要な成果:

  • タゼメトスタットは 固体腫瘍に対する 最初のFDA承認の 遺伝療法です
  • この薬はEZH2の活性を効果的に抑制する.

さらに関連する動画

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles
12:18

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles

Published on: February 1, 2020

6.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K

関連する実験動画

Last Updated: Dec 23, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.8K
LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles
12:18

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles

Published on: February 1, 2020

6.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K
  • SWI/SNF複合体のサブユニットに変異がある腫瘍は,EZH2阻害に対する感受性を示す.
  • 結論:

    • タゼメトスタットは 固体腫瘍の治療の新たな手段を 提供しています 特に表皮遺伝的不調が原因です
    • 薬の有効性は,EZH2を阻害する能力と関連しています.
    • エピテリオイド・サーコマおよび他のSWI/SNF変異がんは,EZH2標的治療の潜在的な候補である.